Andy Chen
Stock Analyst at Wolfe Research
(4.20)
# 491
Out of 5,133 analysts
44
Total ratings
57.69%
Success rate
16.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $79.00 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $26.18 | +90.99% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $74.13 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $454.67 | +20.53% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $810.51 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $11.74 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $21.33 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $369.96 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $49.10 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $79.11 | -38.06% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $21.46 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $72.43 | -24.06% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $17.10 | +256.73% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $48.13 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $54.31 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $31.34 | -36.18% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $21.57 | -11.91% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $103.43 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $25.93 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $493.90 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.99 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $34.11 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $79.48 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $56.18 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $23.44 | -27.47% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $163.72 | -74.35% | 1 | Feb 15, 2024 |
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $79.00
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $26.18
Upside: +90.99%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $74.13
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $454.67
Upside: +20.53%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $810.51
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $11.74
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $21.33
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $369.96
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $49.10
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $79.11
Upside: -38.06%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $21.46
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $72.43
Upside: -24.06%
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $17.10
Upside: +256.73%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $48.13
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $54.31
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $31.34
Upside: -36.18%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $21.57
Upside: -11.91%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $103.43
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $25.93
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $493.90
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $31.99
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $34.11
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $79.48
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $56.18
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $23.44
Upside: -27.47%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $163.72
Upside: -74.35%